Acute myocardial infarction with Type 2 Diabetes
Conditions
Interventions
Empagliflozin group:start with Empagliflozin 10 mg/day and up to 25 mg/day at least 6 months after the intervention
Sitagliptin group:start with Sitagliptin 50 mg/day and up to 100 mg/day at least 6 m
Sponsors
Akashi Medical Center
Wakayama Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients coronary acute myocardial infarction with type 2 diabetes
Exclusion criteria
Exclusion criteria: Patients meeting one of the following conditions will be excluded: 1) poor control:HbA1c(NGSP)>8.5, or under treatment of diabetes, or type 1 diabetes 2)severe liver dysfunction 3)severe renal dysfunction (Cre 2.0 mg/dL) 4)severe heart failure) (NYHA/New York Heart Association stage III or severer) 5)Malignancies or other diseases with poor prognosis 6) pregnant, lactating, and possibly pregnant women and those planning to become pregnant 7) past medical history of hypersensitivity to investigational drugs 8) judged as ineligible by clinical investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in infarct size assessed by BMIPP Scintigraphy 6 months after the intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Composite cardiovascular event rate after 12 months of treatment 2)Change in daily glucose profile (SD, MAGE) 3)Changes of variables as follows from pre-treatment to 6 months after treatment HbA1c(NGSP) and 75g OGTT (glucose and insulin levels after glucose load) the incidence of arrhythmia assessed by Holter ECG the level of BNP 4)Acute changes of variables as follows 3 days before and after the intervention HbA1c(NGSP) and 75g OGTT (glucose and insulin levels after glucose load) the incidence of arrhythmia assessed by Holter ECG the level of BNP | — |
Countries
Japan
Contacts
Public ContactMasaru KURODA
Akashi Medical Center Cardiology
Outcome results
None listed